Michael Leal Thompson
Known title: DirectorCIK: 0001296630
Associated companies
Transaction History
| MTG | ▲ Buy | Grant | 28 | — | 8/20/2026 | View on chart |
| MTG | ▲ Buy | Grant | 29 | — | 5/21/2026 | View on chart |
| MTG | ▲ Buy | Grant | 28 | — | 3/6/2026 | View on chart |
| MTG | ▲ Buy | Grant | 0 | — | 2/13/2026 | View on chart |
| MTG | ▲ Buy | Grant | 5,077 | — | 2/4/2026 | View on chart |
| MTG | ▲ Buy | Grant | 27 | — | 11/20/2025 | View on chart |
| MTG | ▲ Buy | Grant | 27 | — | 8/21/2025 | View on chart |
| MTG | ▲ Buy | Grant | 24 | — | 5/21/2025 | View on chart |
| MTG | ▲ Buy | Grant | 27 | — | 3/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 0 | — | 2/14/2025 | View on chart |
| MTG | ▲ Buy | Grant | 4,898 | $125K | 2/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 34 | — | 11/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 34 | — | 8/22/2024 | View on chart |
| MTG | ▲ Buy | Grant | 35 | — | 5/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 37 | — | 3/5/2024 | View on chart |
| MTG | ▲ Buy | Grant | 1 | — | 2/15/2024 | View on chart |
| MTG | ▲ Buy | Grant | 6,310 | $125K | 2/2/2024 | View on chart |
| MTG | ▲ Buy | Grant | 13 | — | 11/28/2023 | View on chart |
| MTG | ▲ Buy | Grant | 1,959 | $34K | 11/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings
Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings. Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.